Saturday 17 October 2026 Export STXS’s income statement to Excel — free account

Stereotaxis Inc.

STXS Healthcare Medical Instruments & Supplies

Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.01 0.04 −3.81%

Follow STXS

Alert me

Market cap: $105.2M
P/E: 0.0×
Fwd P/E: −8.9×
Dividend yield: —
F-score: 5/9
Altman Z: −12.40
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.07

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 23.08%

Capital & Financial Ratios $m

Market Cap 105.21

Revenue 30.07

Net Income (22.32)

Free Cash Flow (15.50)

Net Debt (10.49)

Current Ratio 1.42

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.90)

P/S ratio 3.36

P/B ratio 8.25

Past 5Y EPS Growth —

This Y EPS Growth 17.33%

Next Y EPS Growth 27.42%

Next Y revenue growth 6.03%

Next 5Y EPS Growth 25.48%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.16%

10-year low 10-year high

P/B against its own 10 years 27.14%

10-year low 10-year high

EV/Sales against its own 10 years 28.86%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	20	12	13	10
Receivables	4	4	10	14
Inventory	8	8	10	13
Other	—	—	—	—
	33	26	34	38

	2023	2024	2025	Q'26
Payables	3	6	5	7
ST’ Debt	—	—	—	—
Other	—	6	5	6
	13	22	22	27

Compound Annual Growth %

	10y	5y	3y
Sales	(1.50%)	3.99%	4.78%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(14.19%)	(16.30%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	8	—	—	—
’25	7	9	7	9	32
’24	7	5	9	6	27
’23	7	8	8	5	27
’22	7	6	8	7	28
’21	9	9	9	8	35
’20	6	5	9	7	27

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(2)	(4)	(4)	(4)	(14)
’24	(2)	(3)	(4)	1	(8)
’23	(3)	(3)	(1)	(2)	(9)
’22	(2)	(1)	(3)	(3)	(8)
’21	0	0	(1)	(1)	(3)
’20	(2)	(1)	0	0	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(2)	(4)	(4)	(4)	(14)
’24	(2)	(3)	(4)	1	(9)
’23	(3)	(3)	(1)	(2)	(10)
’22	(3)	(2)	(3)	(3)	(11)
’21	0	0	(2)	(2)	(4)
’20	(2)	(1)	0	0	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.05)	—	—	—
’25	(0.07)	(0.05)	(0.07)	(0.06)	(0.25)
’24	(0.06)	(0.07)	(0.08)	(0.09)	(0.30)
’23	(0.07)	(0.07)	(0.07)	(0.07)	(0.27)
’22	(0.06)	(0.07)	(0.07)	(0.06)	(0.26)
’21	(0.02)	(0.02)	(0.07)	(0.05)	(0.16)
’20	(0.03)	(0.03)	(0.03)	(0.02)	(0.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	0.47	0.48	0.51	1.07	1.70	4.31	1.55	1.33	1.66	1.54	Analyst estimates 2026–2028 Powerpack
	High	1.95	1.10	1.65	5.82	5.58	10.30	7.22	2.75	3.29	3.59
People
People	Employees	120	117	119	118	120	130	130	122	139	131
	Revenue/emp, $m	0.27	0.27	0.25	0.24	0.22	0.27	0.22	0.22	0.19	0.25
Income, $m
Income, $m	Revenue	32	31	29	29	27	35	28	27	27	32
	Gross margin, %	76.59	65.47	80.52	78.77	71.22	66.34	65.62	55.51	54.22	52.73
	EBT	(5)	(6)	0	(5)	(7)	(11)	(18)	(21)	(24)	(22)
	EBT margin, %	(16.44)	(18.90)	0.40	(15.89)	(24.96)	(30.60)	(64.99)	(77.37)	(89.33)	(66.85)
	Net income	(5)	(6)	0	(5)	(7)	(11)	(18)	(21)	(24)	(22)
	Depreciation	1	1	1	0	0	0	0	0	1	2
Per share, $
Per share, $	Revenue	1.47	1.38	0.56	0.46	0.37	0.46	0.37	0.33	0.32	0.36
	Earnings	(0.54)	(0.32)	(0.03)	(0.10)	(0.11)	(0.16)	(0.26)	(0.27)	(0.30)	(0.25)
	Cash flow	(0.30)	(0.21)	(0.05)	(0.07)	(0.05)	(0.04)	(0.11)	(0.11)	(0.10)	(0.15)
	Capex	(0.02)	0.00	(0.01)	0.00	0.00	(0.02)	(0.03)	0.00	0.00	0.00
	Free cash flow	(0.32)	(0.21)	(0.05)	(0.07)	(0.05)	(0.06)	(0.14)	(0.12)	(0.10)	(0.15)
	Book value	(0.71)	(0.91)	0.14	0.45	0.55	0.52	0.42	0.27	0.13	0.21
	Shares, m	22	23	52	63	73	76	76	81	85	91
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.47	0.61	1.92	11.54	13.90	13.38	5.67	5.64	7.22	6.46
	P/B	0.00	0.00	42.90	14.65	10.70	13.85	6.06	9.23	31.94	15.52
	EV/Sales	0.87	1.17	2.27	10.67	12.39	12.35	4.76	5.00	6.87	6.15
	EV/FCF	(3.94)	(7.66)	(23.67)	(66.39)	(91.78)	(99.59)	(12.42)	(14.08)	(21.69)	(14.44)
Cash, $m
Cash, $m	Operating cash flow	(7)	(5)	(3)	(5)	(4)	(3)	(8)	(9)	(8)	(14)
	Capex	0	0	0	0	0	(1)	(2)	0	0	0
	Free cash flow	(7)	(5)	(3)	(5)	(4)	(4)	(11)	(10)	(9)	(14)
Balance, $m
Balance, $m	Working capital	(16)	(20)	8	27	39	38	29	20	5	11
	Total debt	—	—	—	2	1	6	5	—	—	—
	Net debt	(9)	(4)	(11)	(28)	(43)	(39)	(29)	(20)	(12)	(13)
	Shareholders’ equity	(16)	(21)	7	29	40	39	32	22	11	19
Returns, %
Returns, %	ROA	(59.23)	(46.28)	(9.03)	(19.39)	(16.19)	(20.72)	(34.33)	(46.28)	(57.21)	(46.30)
	ROIC	0.00	0.00	0.00	(698.34)	0.00	(3,457.08)	(394.59)	(865.53)	0.00	(260.75)
	ROE	60.34	30.46	10.43	(50.02)	(27.94)	(35.24)	(65.26)	(103.35)	(226.13)	(234.28)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%	Compare
DXR Daxor Corporation	$59.6M	4.7×	7.6×	−27.62% (below 0%: shrinking)	n/m	−88.56% (below 0%: shrinking)	0.00%	0.00%	Compare
POCI Precision Optics Corp.	$47.7M	— (loss-making)	—	+41.95% (above 0%: growing)	n/m	−45.64% (below 0%: shrinking)	25.34%	(1.21%)	Compare
Median of peers	$92.5M	13.8×	23.5×	+17.40%	—	−67.34%	30.05%	0.00%

All 55 Medical Instruments & Supplies stocks →

Stereotaxis Inc. (STXS) key facts

Strength: Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024.
Stereotaxis Inc. (STXS) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, STXS traded at $1.01, a market capitalization of $105.2 million.
Return on equity was −234.3% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −12.40 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.